travoprost (Travatan®)

Reference No. 2601

Publication date:

18/11/2015

Appraisal information

travoprost (Travatan®) 40 micrograms/ml eye drops

Company:	Alcon Laboratories (UK) Ltd
BNF category:	Eye
NMG meeting date:	09/09/2015
AWMSG meeting date:	21/10/2015

Submission Type:	Limited Submission
Status:	Recommended
Advice No:	3115
Ministerial ratification:	17/11/2015

Current Progress

Submission
received

NMG
meeting

AWMSG
meeting

Ministerial
Ratification

AWMSG advice

Travoprost (Travatan®) is recommended as an option for use within NHS Wales for the decrease of elevated intraocular pressure in paediatric patients aged 2 months to < 18 years with ocular hypertension or paediatric glaucoma.

Final Appraisal Recommendation (FAR)

Download

travoprost (Travatan) 2601 FAR

AWMSG Secretariat Appraisal Report (ASAR)

Download

travoprost (Travatan) 2601 ASAR

Clinical Expert (CE) Summary

Download

travoprost (Travatan) 2601 CE Summary